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REVIEW ARTICLE
Recently Identified Forms of Epidermolysis Bullosa
John A. McGrath
St John’s Institute of Dermatology, King’s College London (Guy’s Campus), London, UK
Epidermolysis bullosa (EB) comprises a collection of clin-
ically diverse inherited blistering diseases that affect the skin 
and, in some subtypes, mucous membranes and other 
organs. Currently classified into four main subtypes (EB sim-
plex, junctional EB, dystrophic EB, and Kindler syndrome, 
mainly based on the level of skin cleavage), the spectrum of 
EB extends to more than 30 clinical subtypes with patho-
genic mutations in at least 18 distinct genes. This review fo-
cuses on three recent additions to variants of EB: all are auto-
somal recessive, and result from mutations in either DST-e 
(coding for epidermal dystonin, also known as the 230 kDa 
bullous pemphigoid antigen, BP230), EXPH5 (coding for 
exophilin-5, also known as Slac2-b), or ITGA3 (coding for the 
integrin alpha-3 subunit). Each of these new forms of EB is re-
viewed with respect to the initial gene discovery, clinical fea-
tures, the current mutation database, and skin pathology. 
Awareness of these recently described forms of EB is helpful 
in the clinical evaluation of patients with EB and in defining 
genotype-phenotype correlation for inherited blistering skin 
diseases. (Ann Dermatol 27(6) 658∼666, 2015)
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INTRODUCTION
Over the past 25 years, enormous advances have been 
made in understanding the clinical and molecular basis of 
epidermolysis bullosa (EB); new phenotypes have been 
described, molecular insights have been gained, and trans-
lational research has launched innovative clinical trials of 
new cell- and gene-based therapies1. Summarizing recent 
data, a schematic of the protein/structural pathology cur-
rently implicated in the pathophysiology of EB is shown in 
Fig. 1. Concerning disease taxonomy, several attempts have 
been made to classify and reclassify EB, with helpful 
guidelines published by an international consensus group2. 
Although elements of the current classification of EB are 
still based on the level of blister formation at or within the 
dermal-epidermal junction or epidermis, these latest guide-
lines introduced an “onion skin” classification, providing a 
workable diagnostic algorithm based on variable access to 
general or specialized skin and molecular laboratory 
tests2. Most people with EB can now be classified into one 
of the existing disease categories, although, over the past 
few years several new clinicopathologic entities have 
been added to the collection of EB disorders. These newly 
reported conditions are often very rare and affect just a 
few individuals or families. Nevertheless, identification and 
recognition of these distinct clinicopathologic entities is 
important in improving clinical skills and gaining better in-
sight into the pathophysiology of skin blistering and the 
macromolecular intricacies of adhesion and signaling that 
maintain healthy skin3. This review focuses on three rela-
tively recent discoveries in EB. All three disorders are au-
tosomal recessive, and comprise two forms of EB simplex 
and one of junctional EB with extracutaneous abnormal-
ities, which result from biallelic mutations in DST-e, 
EXPH5, or ITGA3, respectively. This review describes the 
discovery of these conditions, outlines the clinical mani-
festations, summarizes the current known mutations, and 
places the discoveries in the context of skin pathology and 
the pathophysiology of blistering. 
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Fig. 2. Clinical features associated with autosomal recessive 
mutations in DST-e. An intra-epidermal blister on the heel 
resulting from a homozygous nonsense mutation in DST-e.
Fig. 1. The molecular basis of 
epidermolysis bullosa. Mutations in 
structural components of hemides-
mosomes, desmosomes, corneodes-
mosomes, intermediate filaments, 
actin microfilaments, focal contacts, 
and cell vesicle transport underlie 
a spectrum of skin fragility pheno-
types.
DST-e: autosomal recessive epidermolysis bullosa simplex
Pathogenic mutations in DST-e were first reported in 
20104. Their discovery followed identification of a pa-
rent-related Kuwaiti family with a relatively minor form of 
acral skin blistering. The clues to diagnosis came from 
transmission electron microscopy: the patient’s skin was 
completely lacking in hemidesmosomal inner plaques, 
raising the possibility that the inherent gene pathology lay 
in a protein normally sited within this part of the hemi-
desmosomal complex. A candidate gene approach with 
immunofluorescence microscopy and antibodies to vari-
ous hemidesmosomal inner plaque components demon-
strated a complete absence of immunostaining for the 230 
kDa bullous pemphigoid antigen (BP230). Sanger se-
quencing of DST-e, which encodes the BP230 protein, al-
so known as epidermal dystonin, revealed a homozygous 
nonsense mutation, thus establishing a new form of auto-
somal recessive EB simplex with loss-of-function mutations 
in DST-e. 
DST-e: clinical features
To date, six individuals from six different families with au-
tosomal recessive EB simplex due to DST-e pathology 
have been reported; five individuals were from Kuwait, 
the other patient was from Iran. All were from parent-re-
lated families. In most cases, blistering began at or shortly 
after birth. The blistering differed from more classic lo-
calized forms of EB simplex associated with mutations in 
keratin 5 (KRT5) and keratin 14 (KRT14), on the basis that 
some of the blisters were not directly related to pressure 
points on the soles of the feet or toes and the blisters were 
somewhat larger (up to several centimeters in diameter). 
The sides or dorsae of the feet were often affected (Fig. 2). 
There were also a few other scattered generalized blisters, 
but overall the clinical features were of mild severity. No 
ocular, genitourinary, or other mucosal abnormalities have 
been observed. Blistering has tended to heal without scar-
ring, but in the affected Middle-Eastern patients, post-in-
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Fig. 3. Transmission electron microscopy of the dermal-epidermal 
junction in an individual with autosomal recessive mutations in 
DST-e. (A) Complete lack of hemidesmosomal inner plaques 
(arrows) in skin from an affected individual. (B) Clearly discernible 
inner and outer hemidesmosomal plaques are visible in healthy, 
unaffected skin. Scale bar=0.2 μm.
flammatory hyperpigmentation was common. Although the 
condition is autosomal recessive, a semi-dominant trans-
mission mode is also plausible, given that some hetero-
zygous carriers (e.g., parents of affected cases) recall some 
blistering in childhood that usually improves and then 
stops completely by the teenage years5,6. Notably, the fa-
ther of one the Kuwaiti patients reported some blistering 
during childhood that resolved in adulthood, and both 
heterozygous children of an affected Iranian woman had 
minor skin blistering. 
DST-e: molecular pathology
Thus far, two pathogenic homozygous nonsense muta-
tions in DST-e have been identified4,5. The first case re-
ported was in a parent-related Kuwaiti family4, with 
Sanger sequencing of genomic DNA revealing homo-
zygosity for p.Gln1124*. The DST gene encodes multiple 
transcripts with different tissue expression patterns, but the 
mutation identified in this case is specific to the epidermis, 
which is consistent with the lack of extracutaneous clinical 
findings. The second mutation identified was p.Arg1249*. 
It was reported in an Iranian woman born to consanguineous 
parents5. This mutation is also located within the 
coiled-coil domain of the epidermis-specific isoform of 
dystonin. Subsequently, four other individuals from Kuwait6, 
who were not known to be related to one another, pre-
sented with similar blistering and were all shown to be ho-
mozygous for p.Gln1124*, the mutation that was originally 
identified in a Kuwaiti patient. Haplotype analysis in the 
five pedigrees revealed a shared ∼60 kb block of ge-
nomic DNA across the site of the mutation, consistent 
with a founder effect6. 
DST-e: skin pathology
Strikingly, loss-of-function mutations in DST-e give rise to 
major ultrastructural abnormalities with a complete ab-
sence of the hemidesmosomal inner plaque (Fig. 3), a key 
attachment point for keratin intermediate filaments and 
the location for other major plaque proteins, such as plec-
tin4,5. Therefore, it is perhaps somewhat surprising that 
clinical features associated with complete loss of DST-e 
present with such relatively minor blistering, a finding that 
contrasts with the blistering found among many patients 
with the acquired autoimmune condition bullous pemphi-
goid who have autoantibodies to BP230 (although many 
of the latter also have pathogenic antibodies that target the 
180 kDa bullous pemphigoid antigen). Studies of keratino-
cytes from patients with DST-e mutations have identified 
loss of adhesion and increased cell spreading and migra-
tion7. Mutant cells also display reduced β4 integrin at the 
cell surface and have increased total protein levels of kera-
tin 14 and β1 integrin7. The upregulation of keratin 14 
expression at the protein level might offer partial compen-
sation, which may help to explain the relatively mild blis-
tering phenotype associated with loss of DST-e expression. 
Collectively, these cell biology studies identify a pre-
viously unexpected role for DST-e in regulating keratino-
cyte adhesion and in controlling functional switching be-
tween integrin subtypes in keratinocytes. 
DST-e: clinicopathologic comments
The limited degree of predominately acral skin blistering 
may make it clinically difficult to distinguish autosomal re-
cessive EB simplex with DST-e pathology from other forms 
of EB simplex, although, the presence of larger acral blis-
ters in non-pressure prone sites may be indicative. However, 
the lack of hemidesmosomal inner plaques on transmission 
electron microscopy gives the clearest clue to the under-
lying diagnosis. Alternatively, immunostaining of the pa-
tient’s skin with an antibody to DST-e (BP230) is also like-
ly to show a marked reduction in or complete absence of 
immunostaining, thereby highlighting the candidate gene 
for mutations and the likely diagnosis (Fig. 4). 
EXPH5: autosomal recessive epidermolysis bullosa 
simplex
The identification of EXPH5 as a potential gene for EB was 
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Fig. 5. Clinical features associated with autosomal recessive 
mutations in EXPH5. There is minor trauma-induced blistering 
and erosions on both knees, as well as surrounding patchy 
erythema.
Fig. 4. Immunofluorescence microscopy labeling of skin for DST-e (BP230). (A) In healthy control skin, there is bright linear staining 
at the dermal-epidermal junction. (B) In contrast, in skin from a patient with biallelic DST-e mutations, there is a complete absence 
of immunostaining. Scale bar=50 μm.
made by next-generation sequencing8. Three affected chil-
dren from a parent-related Iraqi family presented with su-
perficial generalized blistering with histological evidence 
of intraepidermal skin fragility and keratin tonofilament 
disruption, predominately in basal keratinocytes. Sanger 
sequencing of known genes for EB simplex, KRT5, KRT14, 
and PLEC (plectin), failed to identify pathogenic mutations; 
therefore, whole exome sequencing was performed, with 
a focus on identifying novel homozygous, potentially dam-
aging variants. A homozygous frame-shift mutation in EXPH5 
was identified. EXPH5 encodes exophilin-5, also known as 
Slac2-b, a Rab27 GTPase with a role in intracellular vesi-
cle transport to the cell membrane9. 
EXPH5: clinical features
So far, seven cases of autosomal recessive EB simplex due 
to EXPH5 pathology have been reported in four different 
families from several countries: Iraq, Germany, the United 
Kingdom, and Pakistan. The initial parent-related Iraqi fam-
ily contained eight siblings, of whom three had similar 
skin fragility8. Starting in early life, affected individuals 
had trauma-induced scale crusts and intermittent blistering 
(Fig. 5). Intact blisters were often rare, but the siblings typi-
cally presented with trauma-induced grazes and scale 
crusts that were sometimes slow to heal. Affected sites re-
covered with very slight scarring and post-inflammatory 
hyperpigmentation. There were no extracutaneous abnor-
malities. In all patients, blistering tended to decrease with 
age. The second individual, from a non-parent-related 
European family, presented with more generalized blister-
ing and large erosions that subsequently became milder, 
with later lesions predominantly consisting of acral vesi-
cles10. In the third case, also from a European family, blis-
tering only became evident after several months when the 
child started to walk11. He experienced widespread small 
erosions and bleeding, the major areas affected being the 
lower back, knees, and ankles. There were no intact blis-
ters and he was able to tolerate sticking plasters without 
harm. In the fourth family, from Pakistan, two siblings had 
scattered vesicles and blisters from birth, with individual 
lesions healing within one to two weeks to leave post-in-
flammatory hypopigmentation12. With increasing age, the 
blistering tendency gradually improved and almost remitted.
EXPH5: molecular pathology
Six different frameshift or nonsense mutations in EXPH5 
have been reported thus far. The first mutation, identified 
in the Iraqi family, was a homozygous frameshift muta-
tion, c.5786delC (p.Pro1929Leufs*8). Then, two European 
cases were shown to be compound heterozygotes for bial-
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Fig. 6. Skin microscopic abnormalities resulting from mutations in EXPH5. (A) Semi-thin section reveals acanthosis and mild 
hyperkeratosis. There is also pallor within the basal keratinocyte layer and evidence of darkly stained, condensed cellular material 
Scale bar=50 μm (Richardson's stain). (B) Transmission electron microscopy confirms a low level, intra-epidermal cleavage (asterisks) 
between basal keratinocyte nuclei and the cell membrane. Scale bar=5 μm. (C) Higher magnification establishes that the intracellular 
darkly stained material seen on light microscopy is composed of aggregated keratin tonofilaments (arrow). Scale bar=0.5 μm. (D) 
Some keratinocytes have numerous perinuclear vesicles (arrow). Scale bar=0.5 μm.
lelic loss-of-function mutations: the mutations in the 
German case were c.1395delC (p.Phe466Leufs*44) and 
c.2897delC (p.Pro966Leufs*11), whereas in the British case 
the mutations comprised c.1947dupC (p.Pro649Profs*11) 
and c.2249C＞A (p.Ser750*). The most recently reported 
case, from Pakistan, involved homozygosity for c.3650T＞
A (p.Leu1217*). All pathogenic mutations were located 
within exon 6 and complete loss of exophilin-5 immunostain-
ing was observed in all three of the cases for which im-
munofluorescence microscopy was performed. In each 
case, the route to molecular diagnosis followed different 
strategies: The first case involved whole exome sequencing. 
The second case was extracted from a panel of 70 un-
diagnosed cases of EB simplex (i.e. previously negative for 
mutations in KRT5, KRT14, and PLEC). In the third case, 
the clue to diagnosis came from transmission electron mi-
croscopy, which revealed large perinuclear collections of 
vesicles in basal keratinocytes (Fig. 6). In contrast, the 
fourth case was diagnosed clinically on the basis of a 
spontaneously improving, autosomal recessive blistering 
disorder during childhood. 
EXPH5: skin pathology
The nature of the pathology in this subtype of EB simplex 
appears to be somewhat different from other EB simplex 
entities in that exophilin-5 is (a) not a structural protein 
and (b) not an integral component of intermediate fila-
ments, hemidesmosomes, or desmosomes13. Indeed, the 
precise role of exophilin-5 in keratinocytes is unknown: it 
is a Rab27B GTPase, with a proposed contribution to the 
regulation of cell membrane traffic, including vesicle for-
mation and vesicle movement along actin and tubulin 
networks. Knockdown experiments in HaCaT cells have 
shown a key role for transport of some vesicles to the cell 
membrane, leading to speculation about keratinocyte in-
tegrity being compromised as a result of defective exo-
some trafficking and release of certain proteins, RNAs, and 
microRNAs from the cell14. Knockdown of EXPH5 also 
leads to reduced cell adhesion to the basement mem-
brane, providing an explanation for the observed skin fra-
gility8. In terms of the cell pathology, there is marked dis-
ruption of the keratin filament network. Indeed, some of 
the keratin filament aggregation shows a basket-weave 
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Fig. 7. Immunofluorescence microscopy labeling of skin for 
exophilin-5. (A) In healthy control skin, there is bright pan-epidermal 
cytoplasmic staining. (B) In contrast, in skin from a patient with 
biallelic EXPH5 mutations, there is a complete absence of 
immunostaining. Scale bar=50 μm.
pattern and ball-like aggregates that are reminiscent of 
generalized severe EB simplex associated with domi-
nant-negative mutations in KRT5 or KRT14. Exophilin-5 
only colocalizes with Rab27B in certain compartments of 
the cell and appears to have a role in controling β4 in-
tegrin function in keratinocytes8. It is not presently known 
how this particular GTPase affects the microtubule and 
keratin filament interaction. Future identification of key 
proteins involved in this connectivity will most likely pro-
vide fascinating new insights into both the pathophysiol-
ogy of skin blistering and skin homeostasis. 
EXPH5: clinicopathologic comments
Clues to the diagnosis of this subtype of autosomal re-
cessive EB simplex can come from both clinical and skin 
biopsy evaluation. First, the finding of relatively mild blis-
tering in someone with a pattern of inheritance consistent 
with autosomal recessive transmission provides a good 
clue. Indeed, there is also a natural history for the skin 
blistering to improve or remit during childhood. Ultra-
structurally, the skin may show abnormal collections of 
cytoplasmic vesicles and, where available, immunostain-
ing with an antibody to exophilin-5 may show a complete 
absence of skin staining (Fig. 7). For next-generation se-
quencing approaches, biallelic loss-of-function mutations 
in EXPH5 will help uncover this diagnosis. 
ITGA3: junctional epidermolysis bullosa
A candidate gene approach was also used to discover the 
first pathogenic mutations in ITGA3, although, the skin 
component of the underlying disorder was minor in com-
parison to the major inflammation affecting the lungs and 
kidneys15. The initial case had minor blistering, and trans-
mission electron microscopy showed cleavage within the 
lamina lucida, some lamina densa reduplication, and the 
complete absence of immunostaining for the α3 integrin 
subunit in the basement membrane of the skin. Sanger se-
quencing subsequently confirmed loss-of-function muta-
tions in ITGA3. Following diagnosis of the initial case, two 
more cases, presenting with nephrotic syndrome, pulmo-
nary inflammation, and minor skin blistering, were also 
Sanger sequenced and further mutations were identified15. 
Subsequently, two further cases have been reported, al-
though neither had skin blistering as part of the pheno-
type16,17.
ITGA3: clinical features
To date, only five cases of EB related to mutations in 
ITGA3 have been described; all presented as very sick ne-
onates and the skin was not the major health concern15-17. 
The first neonate presented within a few hours of birth 
with respiratory difficulty and required assisted ventilation. 
Within two weeks, this neonate developed renal failure 
with massive proteinuria. However, skin fragility did not 
manifest until after three months, with small blisters and 
erosions occurring after minor trauma. The child died be-
fore eight months of age because of pulmonary infection. 
A second neonate presented with respiratory distress at 48 
hours of life, developed nephrotic syndrome at six weeks 
of life, and died from multi-organ failure aged two months; 
skin fragility was not highlighted in this case. The third pa-
tient developed fever and respiratory distress at two 
months of age, proteinuria at five months, and blisters on 
the shins (initially manifesting as erythematous macules) 
from the age of four months. The child died aged 17 
months from multi-organ failure. For the causative gene 
abnormality in these cases, it was evident from the symp-
toms that the candidate gene was expressed in the kid-
neys, lungs, and skin. However, the fourth case presented 
with respiratory distress at birth and nephrotic syndrome 
but no blisters16. There was interstitial lung disease and 
unilateral renal hypoplasia and hydronephrosis; the child 
died from respiratory failure aged 7 months. The fifth case 
presented with respiratory distress at 2 weeks of age re-
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Fig. 8. Transmission electron micro-
scopy of the dermal-epidermal junc-
tion in an individual with autosomal 
recessive mutations in ITGA3. (A) 
There is cleavage formation within 
the lamina lucida consistent with a 
junctional from of epidermolysis 
bullosa. (B) There is also evidence 
of focal reduplication of the lamina 
densa. (C) The ultrastructural appea-
rances of keratin tonofilaments, he-
midesmosomes, and anchoring fibrils 
show no major structural abnormali-
ties. Scale bar=0.5 μm.
quiring ventilator support17. There was interstitial lung dis-
ease, chest infections and renal anomalies (crossed fused 
renal ectopia) and nephrotic syndrome; dermatologic 
changes were limited to sparse hair and toe nail dystrophy 
which were evident from five months. The child died be-
fore the age of 7 months from pulmonary infection.
ITGA3: molecular pathology 
The first three described cases of EB related to mutations 
in ITGA3 were published together in a single report15. All 
patients were from parent-related families and were identi-
fied has having homozygous mutations. The first case, 
from Southern Italy, had a homozygous frameshift muta-
tion, c.1173_1174del (p.Pro392Valfs*2). The second case, 
from Gaza, had a homozygous acceptor splice site muta-
tion, c.1538-1G＞A. The third case, from Pakistan, had a 
homozygous missense mutation, c.1883G＞C (p.Arg628Pro) 
that occurred within the extracellular domain of α3 in-
tegrin, which may also compromise exon splicing. The 
mutation in the fourth case (from The Netherlands) was al-
so a homozygous missense mutation, c.1045G＞T (p.Ala-
349Ser)16, as was the mutation in the fifth case, c.1387C＞
T (p.Arg463Trp)17. Clues to the molecular pathology of the 
first case came from skin histology and immunohistoche-
mistry, with evident disruption of the basement membrane 
and a complete absence of immunostaining for α3 in-
tegrin15. The other two cases in the initial report were di-
agnosed by screening DNA for mutations in ITGA3 from a 
DNA archive of eight unrelated patients with congenital 
nephrotic syndrome15. Case four was diagnosed following 
exclusion of other candidate genes, homozygosity map-
ping and direct Sanger sequencing of ITGA316, whereas in 
case five, skin immunohistochemistry was used to identify 
α3 integrin as the candidate gene despite the lack of skin 
fragility clinically17.
ITGA3: skin pathology
The alpha-3 integrin subunit normally dimerizes with the 
β1 integrin subunit within focal contacts at the dermal-ep-
idermal junction18. In the first patient with loss-of-function 
mutations in ITGA3, transmission electron microscopy 
showed some structural similarities with those previously 
reported in α3 integrin knockout mice19. Notably, the pa-
tient’s skin had a thin, discontinuous lamina densa. Although 
the lamina densa was typically located in the blister floor, 
it was occasionally adhered to cell fragments, indicating 
multiple levels of cleavage in and around the basement 
membrane15. Although the skin pathology showed some 
histological overlap with Kindler syndrome, the candidate 
gene was identified by the complete lack of α3 integrin 
immunoreactivity in the patient’s skin. Initial skin biopsy 
findings from patient three in the initial report that are pre-
sented for the first time in this review, revealed cleavage 
mostly within the lamina lucida and focal reduplication of 
the basement membrane, but normal hemidesmosome-an-
choring fibril complexes (Fig. 8). In this case, immunostain-
ing for the α3 integrin subunit was completely absent, in 
contrast to a normal staining intensity and pattern for the 
β1 integrin subunit (Fig. 9), consistent with a capacity for 
β1 integrin to dimerize with other integrin subunits20. 
Functional studies in three cases have demonstrated the 
deleterious effects of the mutations (p.Ala349Ser, c.1538-1
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Fig. 9. Immunofluorescence micro-
scopy labeling of skin for the α3 
integrin and β1 integrin subunits. 
(A) In healthy control skin, there is 
α3 integrin labeling at the cell 
margins of basal keratinocytes. (B) 
In contrast, in skin from a patient 
with biallelic ITGA3 mutations, 
there is a complete absence of α3 
integrin immunostaining. (C) Immu-
nostaining for β1 integrin in healthy 
control skin shows a similar pattern 
of labeling to α3 integrin. (D) In 
skin from a patient with biallelic 
ITGA3 mutations, no abnormalities 
in β1 integrin labeling are noted, 
with the appearances resembling 
the healthy control skin. Scale bar= 
50 μm.
G＞A, and p.Arg463Trp) on α3 integrin structure, proc-
essing and dimerization16,17,21.
ITGA3: clinicopathologic comments
Clues to diagnosing this rare form of EB relate to the major 
clinical features of lung and kidney inflammation22. In the 
presence of severe respiratory distress, lung infiltration 
and infection, as well as nephrotic syndrome and renal 
failure, and the finding of minor skin blistering that starts 
between two to four months of life, then skin immuno-
staining for α3 integrin or Sanger sequencing of ITGA3 is 
recommended for candidate gene screening. The con-
stellation of clinical features in this genodermatosis re-
flects the predominant tissue expression of α3 integrin in 
the kidneys, lungs, and skin. Nevertheless, it is clear that 
skin blistering is either mild or absent in this disorder and 
thus whether the phenotypic consequences of ITGA3 mu-
tations should remain as part of the designated spectrum 
of EB, defined as a group of inherited blistering skin dis-
eases, or not, is debatable.
CONCLUSIONS
This review has described the salient clinical and molec-
ular features associated with three recently described 
forms of EB. Although these disorders are rare, under-
standing their nature allows their recognition as distinct 
clinicopathologic entities and their clinical diagnosis in 
similar cases. Moreover, all cases are associated with 
loss-of-function mutations, giving some indication as to 
the human consequences of complete loss of expression 
of these specific proteins. Thus, the clinical, pathology, 
and molecular data provide an improved understanding of 
the mechanisms underlying skin integrity, whilst high-
lighting some of the compensatory processes that may 
occur. In future, it is most likely that a small number of 
other novel forms of EB will be identified that further add 
to what is known about the pathophysiology of skin 
blistering.
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